Earnings Releases·Nov 6, 2026, 6:27 AM ET

Elanco Animal Health — Third Quarter 2026 Earnings Summary

**Financial Performance:** Q3 2026 revenue reached $1.265 billion (up 11% YoY, 9% organic constant currency), while adjusted net income surged 45% to $136 million ($0.27 EPS) and adjusted EBITDA rose 23% to $243 million, improving the margin to 19.5%.
**Guidance Revisions:** The company raised full-year 2026 guidance across all key metrics, projecting revenue of $5.155–$5.18 billion, adjusted EBITDA of $1.05–$1.065 billion, and adjusted EPS of $1.17–$1.20, with Q4 revenue guidance set at $1.190–$1.215 billion.
**Strategic Outlook:** Early 2027 outlook targets mid-single digit organic revenue growth and low-double digit EPS growth; net leverage decreased to 2.9x, unlocking accelerated capital allocation flexibility, while key products Zenrelia and Credelio Quattro continue to gain market share.
**Segment & Operational Highlights:** Pet Health revenue grew 14% YoY and Farm Animal revenue rose 6%, driven by 4% price increases and the April 2026 acquisition of AHV International; the company also announced the appointment of Jamie Preston as EVP and Chief People Officer.